On April 30, 2026, the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. The public comment period closes June 29, 2026. If finalized, this would eliminate the regulatory pathway for large-scale compounding of these three GLP-1 medications — even if new shortages emerge.
What This Actually Means
The proposal targets 503B outsourcing facilities specifically. These are the large-scale compounding operations that supply many telehealth providers with their medication inventory. A 503B exclusion would mean these facilities could no longer compound semaglutide, tirzepatide, or liraglutide regardless of market conditions.
503A pharmacies — smaller, patient-specific compounders — operate under different rules and may be less directly affected, though the regulatory signal is clear: the FDA views compounded GLP-1s as a temporary solution, not a permanent market category.
The Safety Data Behind the Decision
The FDA's position isn't arbitrary. As of early 2025, the agency had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 reports tied to compounded tirzepatide. Many involved dosing errors from patients self-administering incorrect doses from multi-dose vials — some requiring hospitalization.
These reports, combined with the end of both semaglutide and tirzepatide shortages, gave the agency the regulatory opening to act.
What Happens to Current Patients?
Nothing changes immediately. The comment period runs through June 29, and any final rule would take additional months to implement. Current patients on compounded GLP-1s should continue their treatment as prescribed while monitoring developments.
Several organizations — including the National Community Pharmacists Association and the Alliance for Pharmacy Compounding — are expected to file comments opposing the exclusion. The outcome is far from certain.
What to Do Right Now
If you're on compounded GLP-1s, don't panic. Continue your current treatment. If you're considering starting, both compounded and brand-name options remain available today. Choose a provider with strong pharmacy sourcing regardless of what the FDA decides.
Your Options Today
Whether you're hedging against regulatory changes or starting fresh, these providers offer solid options across both compounded and brand-name GLP-1 medications.
Sunlight $159/mo sema, $239/mo tirz · LegitScript certified. Flat pricing — $159 first month, $179 ongoing (semaglutide). No membership, free shipping, HSA/FSA.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.
Sesame Care From $99/visit · Prescribes FDA-approved brand-name medications only. Accepts insurance. No subscription lock-in.
Prescribes FDA-approved brand-name medications only.
Oak Longevity $130/mo flat · One of the lowest flat-rate prices available. $130/mo semaglutide, $199/mo tirzepatide at any dose. Free coaching.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.